Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (filing under "Pluri Inc." in metadata)
Filing Type: Form 8-K (Current Report)
Report Date: November 1, 2011
Event Date: October 30, 2011
Context: The registrant's wholly owned Israeli subsidiary, Pluristem Ltd., entered into a material definitive agreement for the design and construction of a new bio-pharmaceutical manufacturing facility.
Key Financial Metrics
This filing reports on a specific contractual agreement and does not provide comprehensive financial statements (e.g., revenue, profit, cash flow, or debt levels) for the reporting period.
- Total Contract Consideration: NIS 22,800,000 (approximately $6,246,575 USD based on an exchange rate of $1 = NIS 3.65), plus value added tax.
- Payment Structure: Cash and/or up to 2,000,000 shares of the registrant's Common Stock.
- Termination Penalty: $250,000 payable if Pluristem terminates the agreement for convenience, in addition to payments for services rendered.
Material Changes and Project Details
The primary material change is the execution of a turn-key project agreement with Biopharmax Group (1996) Ltd. to build a facility meeting U.S., Canadian, Israeli, and European regulatory authorities' requirements and current Good Manufacturing Practices (cGMP).
- Timeline: The facility is to be leased starting January 2012, with project completion planned for the fourth calendar quarter of 2012.
- Contractor Obligations: The Contractor is subject to penalties for failing to meet the agreed time schedule.
- Equity Component: If the Contractor elects to receive shares, the value is calculated based on the Nasdaq closing price on the issuance date. If shares are immediately sold, the net cash proceeds are deducted from the aggregate consideration owed.
Outlook, Risks, and Contingencies
Management Commentary: The agreement includes performance guarantees from the Contractor. Pluristem retains the right to terminate the agreement at any time via written notice.
Risks and Contingencies:
- Completion Risk: The project is scheduled for completion in Q4 2012; delays may trigger penalties against the Contractor.
- Termination Cost: A fixed penalty of $250,000 applies if the company terminates the contract for convenience.
- Regulatory Compliance: The facility must meet strict cGMP standards across multiple jurisdictions.
Investor Verification Checklist
- Verify the current market price of Pluristem Therapeutics Inc. common stock to assess the potential dilution impact of the 2,000,000 share option.
- Confirm the exchange rate used for the NIS to USD conversion if evaluating the total cash outlay.
- Review the specific terms of the "performance guarantees" provided by Biopharmax Group.
- Monitor the project timeline to ensure the Q4 2012 completion date is met to avoid potential delays in manufacturing capabilities.